目的 对基孔肯雅热抗病毒研究进行文献计量分析，揭示其研究现状与热点，为感染防控和药物研发提供参考。方法 以Web of Science核心合集为数据源，检索自建库以来至2025年8月10日的相关文献。使用CiteSpace和VOSviewer对发文量、国家、期刊、机构、作者及关键词进行可视化分析；采用Excel 2019归纳药物关键词并统计频次。结果 共纳入文献583篇，2004—2025年发文量整体呈上升趋势。美国发文量最高；发文量前3的作者为Merits Andres、Neyts Johan和Delang Leen；Antiviral Research为发文最多的期刊；核心研究力量主要集中在以塔尔图大学为代表的综合性高校和以巴斯德研究所为代表的传染病研究机构。关键词分析显示，基孔肯雅病毒（chikungunya virus）、复制（replication）、感染（infection）为高频核心词，研究主题聚焦于病毒复制、感染与鉴定，涵盖分子对接、基因表达、抑制剂筛选等方向，涉及动物模型构建及交叉病毒研究。药物关键词频次分析显示，抗病毒药物研究以化学药为主，其中小分子抑制剂最为常见，氯喹和利巴韦林出现频次较高；生物药、中药及天然产物研究相对分散。结论 基孔肯雅热抗病毒研究仍处于早期阶段，临床可用药物和特异性疫苗缺乏。研究重心由传播监测转向药物筛选与靶点探索，结构生物学、分子对接及反向遗传学等新技术推动了候选药物的研发。未来应强化药物再利用、多靶点策略及天然产物活性成分系统的筛选，挖掘黄酮类、二萜类化合物及中药在症状干预中的潜力，依托跨学科方法与国际合作，提升研发效率与临床转化率，为病毒防控提供创新思路。

Objective To conduct a bibliometric analysis of antiviral research on chikungunya fever, to reveal the current status and research hotspots, and to provide references for infection prevention and drug development. Methods Publications related to antiviral studies on chikungunya fever were retrieved from the Web of Science core collection from database inception to August 10, 2025. CiteSpace and VOSviewer were used for visual analysis of publication output, countries, journals, institutions, authors, and keywords, wheras Excel 2019 was employed to summarize and calculate the frequency of drug-related keywords. Results A total of 583 publications were included, showing an overall upward trend in output between 2004 and 2025. The United States had the highest number of publications; the top three productive authors were Merits Andres, Neyts Johan, and Delang Leen, Antiviral Research was the leading journal in terms of publications, and core research forces were concentrated in comprehensive universities such as the University of Tartu and infectious disease institutes such as the Institut Pasteur. Keyword analysis indicated that “chikungunya virus” “replication” “infection” were high-frequency core terms. Research themes mainly focused on viral replication, infection, and identification, encompassing molecular docking, gene expression, and inhibitor screening, as well as animal model construction and cross-virus studies. Keyword frequency analysis of antiviral drugs showed that chemical drugs dominated the field, with small-molecule inhibitors being the most common, and chloroquine and ribavirin appearing most frequently, studies on biologics, traditional Chinese medicine, and natural products were relatively scattered. Conclusion Antiviral research on chikungunya virus remains in its early stages, with a paucity of clinically approved therapeutics and specific vaccines. Research priorities have shifted from transmission surveillance toward drug discovery and target-based investigations, with emerging technologies—including structural biology, molecular docking, and reverse genetics—facilitating candidate compound development. Future research should prioritize drug repurposing, multi-target strategies, and systematic evaluation of bioactive natural products, particularly flavonoids, diterpenoids, and traditional Chinese medicinal compounds for symptomatic intervention. Integrating interdisciplinary methodologies and fostering international collaboration are essential to enhance research efficiency, accelerate clinical translation, and provide innovative avenues for chikungunya virus prevention and control.

R286.87；G350

广东省自然科学基金面上项目（2025A1515011256）；广东省自然科学基金粤穗联合青年基金项目（2023A1515110849）；广东省中医药局科研平台专项（20254040）；广东省医学科研基金项目（B2024112）；广州中医药大学高水平医院共建项目科研专项项目（GZYZS2024G09）；国家自然科学基金项目（82505441）；中医药广东省实验室科技研发培植项目（HQL2024PZ043）；广州中医药大学青年拔尖人才“揭榜挂帅”团队项目（负责人：郑文江）